SCHEMBL5396502

SCHEMBL5396502

CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cc([N+](=O)[O-])c[nH]1)C(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.56
CDK2 P24941 3/20 0.55
KDR P35968 3/20 0.53
PDGFRB P09619 3/20 0.52
JAK3 P52333 1/20 0.52
NTRK1 P04629 1/20 0.47
FCER2 P06734 1/20 0.47
SYK P43405 1/20 0.47
NTRK3 Q16288 1/20 0.47
NTRK2 Q16620 1/20 0.47
PDPK1 O15530 2/20 0.47
GSK3B P49841 3/20 0.46
RET P07949 2/20 0.45
CCNE1 P24864 1/20 0.45
LCK P06239 2/20 0.44
FYN P06241 2/20 0.44
YES1 P07947 2/20 0.44
FGFR1 P11362 2/20 0.44
NOX4 Q9NPH5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133388 0.84 GSK3B (0.60) SRCCDK2KDRGSK3BRET
SCHEMBL5728093 0.80 TLK2 (0.61) SRCCDK2KDRPDGFRBJAK3
SCHEMBL5728094 0.80 TLK2 (0.61) SRCCDK2KDRPDGFRBJAK3
SCHEMBL5363782 0.80 NOX4 (0.57) SRCCDK2KDRPDGFRBJAK3
SCHEMBL5728095 0.79 PDPK1 (0.73) SRCCDK2KDRPDGFRBJAK3
SCHEMBL5363321 0.79 PDPK1 (0.73) SRCCDK2KDRPDGFRBJAK3
SCHEMBL5405110 0.79 CDK2 (0.57) SRCCDK2KDRPDGFRBNTRK1
SCHEMBL5728098 0.79 MAPT (0.64) SRCKDRPDGFRBJAK3NTRK1
SCHEMBL5728101 0.79 MAPT (0.64) SRCKDRPDGFRBJAK3NTRK1
SCHEMBL5368250 0.78 SRC (0.55) SRCCDK2KDRPDGFRBNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 SRC 297/4885CDK2 95/4885KDR 1657/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM SRC 663/4885CDK2 172/4885KDR 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.